Clinical Trial Update: Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing low-dose PK-guided extended-half-life FVIII concentrates to standard prophylaxis in adults with severe Hemophilia A without inhibitors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• FVIII (low-dose PK-guided extended-half-life concentrate)

Snippet

Sponsor: Chulalongkorn University | Conditions: Severe Hemophilia A Without Inhibitor | Phase 4 | Status: COMPLETED